Vortioxetine: a review of efficacy,safety and tolerability with a focus on cognitive symptoms in major depressive disorder |
| |
| Authors: | Mayce Al-Sukhni Nadia A Maruschak Roger S McIntyre |
| |
| Affiliation: | 1. General Psychiatry and Acute Care Units, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T 1R8, Canada;2. University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, MP 9-325, Toronto, ON M5T 2S8, Canada;3. University of Toronto, 399 Bathurst Street, MP 9-325, Toronto, ON M5T 2S8, Canada +1 416 603 5279;4. +1 416 603 5368;5. roger.mcintyre@uhn.ca;6. Head, University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, MP 9-325, Toronto, ON M5T 2S8, Canada |
| |
| Abstract: | ![]()
Introduction: Vortioxetine is a pharmacodynamically novel antidepressant that exerts effects on various neurotransmitters including serotonin, noradrenaline, dopamine, glutamate, histamine and acetylcholine. Its efficacy in the symptomatic management of major depressive disorder (MDD) has been established in several short- and long-term trials. Vortioxetine has also demonstrated independent pro-cognitive effects in adults with MDD.Areas covered: This report provides a concise review of the pharmacology, efficacy and safety of vortioxetine as they pertain to cognition.Expert opinion: The significant impact of cognitive dysfunction in MDD has achieved increased consideration among researchers over the past decade. Vortioxetine is the first antidepressant agent to demonstrate meaningful clinical efficacy in the improvement of cognition in adults with MDD, independent of improvement in affective symptomatology. These results provide the impetus for further study into the potential pro-cognitive effects of vortioxetine in other conditions wherein cognitive dysfunction is prominent. |
| |
| Keywords: | antidepressant cognition major depressive disorder neurotransmitter vortioxetine |
|
|
